 |
|
Press Release
Press release list >
Dr. Mark W. Schwartz joins Apthera as President & CEO
Mr. Edward L. Jacobs also appointed to Apthera's Board
Scottsdale, Arizona - January 8, 2010 - Apthera, Inc. ("Apthera")
today announced the appointments of Dr. Mark W. Schwartz to the position of
President and Chief Executive Officer and Mr. Edward L. Jacobs to the Apthera
Board as an independent director. Apthera also appointed Dr. Schwartz to the
Board.
As President and CEO, Dr. Schwartz's primary responsibilities are to
lead the Company's fundraising and partnering efforts and accelerate its
product development activities. "We are very pleased to bring Dr. Schwartz
onto the Apthera team. Mark brings to Apthera a proven track record of raising
institutional capital and forming collaborative product development partnerships.
Our objective will be to accelerate the development of Apthera's lead
product, NeuVaxTM, an active specific immunotherapy for early-stage breast cancer,"
said Ira Z. Leiderman, Chairman of Apthera.
"I am excited to be appointed Apthera's President and CEO. Apthera
represents a rare opportunity with its late-stage clinical program targeting
women with triple-negative breast cancer. The FDA has accepted Apthera's
Phase III Special Protocol Assessment (SPA) for NeuVax and the Company is entering
discussions for a corporate partnership to fund this pivotal stage of clinical
development," said Dr. Schwartz.
Edward Jacobs presently serves as the President and CEO of Ascalon International,
Inc., a private oncology product development company. "We are excited
that Mr. Jacobs has joined the Apthera board. Ed has spent his career in the
field of oncology from the business side and brings to Apthera significant industry
contacts and deal making expertise," stated Robert Kennedy, Chief Financial
Officer.
About Apthera
Apthera, Inc. is a privately-held, Arizona-based biotechnology company developing
a pipeline of peptide-based active specific immunotherapies for cancers that
express HER2/neu, a well-validated and established oncology target. The Company's
lead product, NeuVax, contains a patented peptide which has been documented
over the past 8 years to elevate or boost pre-existing anti-cancer immunity
in cancer patients. NeuVax's initial indication is for front-line adjuvant
therapy of early-stage breast cancer patients who express HER2/neu but don't
qualify for trastuzumab (Herceptin®) or lapatinib (Tykerb®). For more
information about the Company visit www.apthera.com.
This news release contains forward-looking statements. These statements are
not historical facts and are subject to risks and uncertainties which could
cause actual results and the timing of certain events to differ materially from
those set forth in or implied herein including, without limitation, risks associated
with clinical development, regulatory approvals, product commercialization,
intellectual property claims litigation and other risks associated with the
Company's proposed activities.
Contact Apthera:
Robert Kennedy, CFO
(480) 348-9705
rkennedy@apthera.com
www.apthera.com
|
